CN100348278C - Reinforced compound nanometer apatite material and its prepn process - Google Patents
Reinforced compound nanometer apatite material and its prepn process Download PDFInfo
- Publication number
- CN100348278C CN100348278C CNB2005100223265A CN200510022326A CN100348278C CN 100348278 C CN100348278 C CN 100348278C CN B2005100223265 A CNB2005100223265 A CN B2005100223265A CN 200510022326 A CN200510022326 A CN 200510022326A CN 100348278 C CN100348278 C CN 100348278C
- Authority
- CN
- China
- Prior art keywords
- polyamide
- apatite
- nano
- composition
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229910052586 apatite Inorganic materials 0.000 title claims abstract description 147
- 239000000463 material Substances 0.000 title claims abstract description 102
- 150000001875 compounds Chemical class 0.000 title claims abstract description 62
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 title claims abstract description 47
- 238000000034 method Methods 0.000 title claims description 16
- 230000008569 process Effects 0.000 title claims description 5
- 239000000203 mixture Substances 0.000 claims abstract description 93
- 229920002647 polyamide Polymers 0.000 claims abstract description 60
- 239000002904 solvent Substances 0.000 claims abstract description 52
- 239000004952 Polyamide Substances 0.000 claims abstract description 40
- 238000002360 preparation method Methods 0.000 claims abstract description 33
- 239000002270 dispersing agent Substances 0.000 claims abstract description 29
- 239000011268 mixed slurry Substances 0.000 claims abstract description 21
- 239000002861 polymer material Substances 0.000 claims abstract description 21
- 239000002131 composite material Substances 0.000 claims description 53
- 239000000470 constituent Substances 0.000 claims description 45
- 229920001577 copolymer Polymers 0.000 claims description 37
- -1 dimethyl sulfoxine Chemical compound 0.000 claims description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 108010020346 Polyglutamic Acid Proteins 0.000 claims description 18
- 229920002643 polyglutamic acid Polymers 0.000 claims description 18
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 17
- 239000005977 Ethylene Substances 0.000 claims description 17
- 238000003756 stirring Methods 0.000 claims description 17
- 238000009835 boiling Methods 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 229920002292 Nylon 6 Polymers 0.000 claims description 13
- SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical compound CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 239000004094 surface-active agent Substances 0.000 claims description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 9
- 108010050934 polyleucine Proteins 0.000 claims description 9
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 8
- 229920002302 Nylon 6,6 Polymers 0.000 claims description 8
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 8
- 102000008186 Collagen Human genes 0.000 claims description 7
- 108010035532 Collagen Proteins 0.000 claims description 7
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 7
- 229920001436 collagen Polymers 0.000 claims description 7
- SONHXMAHPHADTF-UHFFFAOYSA-M sodium;2-methylprop-2-enoate Chemical compound [Na+].CC(=C)C([O-])=O SONHXMAHPHADTF-UHFFFAOYSA-M 0.000 claims description 7
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 claims description 6
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical group O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 claims description 6
- BYEVBITUADOIGY-UHFFFAOYSA-N ethyl nonanoate Chemical compound CCCCCCCCC(=O)OCC BYEVBITUADOIGY-UHFFFAOYSA-N 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 239000008273 gelatin Substances 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 229920002521 macromolecule Polymers 0.000 claims description 5
- 239000002736 nonionic surfactant Substances 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 4
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical compound CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004793 Polystyrene Substances 0.000 claims description 4
- 235000020057 cognac Nutrition 0.000 claims description 4
- CRSOQBOWXPBRES-UHFFFAOYSA-N neopentane Chemical compound CC(C)(C)C CRSOQBOWXPBRES-UHFFFAOYSA-N 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 4
- 239000004626 polylactic acid Substances 0.000 claims description 4
- 229920002223 polystyrene Polymers 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 229920000571 Nylon 11 Polymers 0.000 claims description 3
- 229920000299 Nylon 12 Polymers 0.000 claims description 3
- 229920003189 Nylon 4,6 Polymers 0.000 claims description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 3
- 229920003232 aliphatic polyester Polymers 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 238000010533 azeotropic distillation Methods 0.000 claims description 3
- 229920001400 block copolymer Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- YEJSPQZHMWGIGP-UHFFFAOYSA-N dl-glutamic acid dimethyl ester Natural products COC(=O)CCC(N)C(=O)OC YEJSPQZHMWGIGP-UHFFFAOYSA-N 0.000 claims description 3
- 229960002591 hydroxyproline Drugs 0.000 claims description 3
- 229920001912 maleic anhydride grafted polyethylene Polymers 0.000 claims description 3
- 125000005395 methacrylic acid group Chemical group 0.000 claims description 3
- SEWIYICDCVPBEW-UHFFFAOYSA-N methyl glutamate Chemical compound COC(=O)C(N)CCC(O)=O SEWIYICDCVPBEW-UHFFFAOYSA-N 0.000 claims description 3
- 229920000728 polyester Polymers 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 229960004799 tryptophan Drugs 0.000 claims description 3
- OAYXUHPQHDHDDZ-UHFFFAOYSA-N 2-(2-butoxyethoxy)ethanol Chemical compound CCCCOCCOCCO OAYXUHPQHDHDDZ-UHFFFAOYSA-N 0.000 claims description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical class ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 239000000835 fiber Substances 0.000 claims description 2
- 239000010408 film Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 230000012010 growth Effects 0.000 abstract description 8
- 230000015556 catabolic process Effects 0.000 abstract description 4
- 238000006731 degradation reaction Methods 0.000 abstract description 4
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 48
- 239000002002 slurry Substances 0.000 description 36
- 230000004048 modification Effects 0.000 description 17
- 238000012986 modification Methods 0.000 description 17
- 229920000642 polymer Polymers 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 239000007788 liquid Substances 0.000 description 11
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 11
- 238000005303 weighing Methods 0.000 description 11
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 10
- 229920001684 low density polyethylene Polymers 0.000 description 10
- 239000004702 low-density polyethylene Substances 0.000 description 10
- 210000000988 bone and bone Anatomy 0.000 description 9
- 239000003607 modifier Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000012620 biological material Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 6
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 6
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 6
- 238000013019 agitation Methods 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 239000000600 sorbitol Substances 0.000 description 6
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 6
- 229940117972 triolein Drugs 0.000 description 6
- 239000011575 calcium Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 5
- 229920001903 high density polyethylene Polymers 0.000 description 5
- 239000004700 high-density polyethylene Substances 0.000 description 5
- 230000010355 oscillation Effects 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 239000004699 Ultra-high molecular weight polyethylene Substances 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000004067 bulking agent Substances 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 210000000963 osteoblast Anatomy 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 229920000785 ultra high molecular weight polyethylene Polymers 0.000 description 4
- 238000002525 ultrasonication Methods 0.000 description 4
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 229920001747 Cellulose diacetate Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229910052788 barium Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 239000004567 concrete Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000016507 interphase Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229920006112 polar polymer Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical class C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- XJDDLMJULQGRLU-UHFFFAOYSA-N 1,3-dioxane-4,6-dione Chemical compound O=C1CC(=O)OCO1 XJDDLMJULQGRLU-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- RTDFGKYXQPTZHZ-UHFFFAOYSA-N C(CCCCCCCC)(=O)OCC.OCC(O)CO.C(C)O Chemical compound C(CCCCCCCC)(=O)OCC.OCC(O)CO.C(C)O RTDFGKYXQPTZHZ-UHFFFAOYSA-N 0.000 description 1
- 229910014497 Ca10(PO4)6(OH)2 Inorganic materials 0.000 description 1
- 229920001732 Lignosulfonate Polymers 0.000 description 1
- 239000004117 Lignosulphonate Substances 0.000 description 1
- 235000019738 Limestone Nutrition 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- UEBBZHLAABCPPA-UHFFFAOYSA-N OC.CCCCCCCCC(=O)OCC Chemical compound OC.CCCCCCCCC(=O)OCC UEBBZHLAABCPPA-UHFFFAOYSA-N 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000005137 deposition process Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- AEDZKIACDBYJLQ-UHFFFAOYSA-N ethane-1,2-diol;hydrate Chemical compound O.OCCO AEDZKIACDBYJLQ-UHFFFAOYSA-N 0.000 description 1
- BDWFYHUDXIDTIU-UHFFFAOYSA-N ethanol;propane-1,2,3-triol Chemical compound CCO.OCC(O)CO BDWFYHUDXIDTIU-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- PRZYBBKOPCYXBD-UHFFFAOYSA-N ethyl hexanoate;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCC(=O)OCC PRZYBBKOPCYXBD-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000010335 hydrothermal treatment Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229920000554 ionomer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 235000019357 lignosulphonate Nutrition 0.000 description 1
- 239000006028 limestone Substances 0.000 description 1
- 229920000092 linear low density polyethylene Polymers 0.000 description 1
- 239000004707 linear low-density polyethylene Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- ADFPJHOAARPYLP-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;styrene Chemical compound COC(=O)C(C)=C.C=CC1=CC=CC=C1 ADFPJHOAARPYLP-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- WWECJGLXBSQKRF-UHFFFAOYSA-N n,n-dimethylformamide;methanol Chemical compound OC.CN(C)C=O WWECJGLXBSQKRF-UHFFFAOYSA-N 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229940085991 phosphate ion Drugs 0.000 description 1
- 229910052585 phosphate mineral Inorganic materials 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001432 poly(L-lactide) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000131 polyvinylidene Polymers 0.000 description 1
- 229920002717 polyvinylpyridine Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- JHJUUEHSAZXEEO-UHFFFAOYSA-M sodium;4-dodecylbenzenesulfonate Chemical compound [Na+].CCCCCCCCCCCCC1=CC=C(S([O-])(=O)=O)C=C1 JHJUUEHSAZXEEO-UHFFFAOYSA-M 0.000 description 1
- RNVYQYLELCKWAN-UHFFFAOYSA-N solketal Chemical compound CC1(C)OCC(CO)O1 RNVYQYLELCKWAN-UHFFFAOYSA-N 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000007785 strong electrolyte Substances 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Landscapes
- Materials For Medical Uses (AREA)
Abstract
The present invention relates to a reinforced compound nanometer apatite material and a preparation method thereof. Basic components of the compound material are compounds formed by nanometer apatite components and at least one kind of medical polymer materials in an azeotropic solution system. The nanometer apatite components can be nanometer level apatites or osteoid apatites, and medical polymer material components can be at least one kind of polyamide or non-polyamide high molecular polymer materials. The preparation comprises the following steps: mixed slurry of nanometer apatite components and dispersing agents is mixed with high molecular material solution obtained by dissolving medical polymer materials and high molecular material good solvents which can form an azeotropic system with the dispersing agents, and the mixture is sufficiently stirred so as to carry out the composition to obtain the compound material in the temperature range 5 DEG C higher than an azeotropic point of the mixed material system and 80 DEG C lower than the azeotropic point. The apatite content, the material strength, the hydrophilicity and hydrophobicity, and the degradation rate of the compound material can be regulated according to growth requirements of organisms and cell attachments of different types to obtain better performance.
Description
Technical field
What the present invention relates to is that a kind of bone that can be used as is repaired reinforced compound nanometer apatite material of substitution material and preparation method thereof.
Background technology
Fast development along with the biological product industry, depend merely on traditional homogenous material and can not satisfy tissue repair and the alternative goods performance requirement of Gao Gengyan more, development has the inexorable trend that good mechanical compatibility and bioactive composite have become international biomaterial research concurrently.
Tradition mainly contains the preparation method of composite, adopt the kneading blend (as Chinese patent application 94191562.X) of apatite oven dry powder/lyophilized powder/ceramics and macromolecular material, melting blending (as S.M.Rea et al., Biomaterials 25 (2004) 4503-4512; M.Wang, W.Bonfield, Biomaterials 22 (2001): 1311-1320), and mold pressing under the High Temperature High Pressure (Chinese patent application number 02148789.8) and solution blending compound (as patent No. ZL 98125670.8 and Chinese patent application number 02138342.1) etc.In these methods,, be the micron-scale phase separation shape between the interface, thereby greatly influenced the performance of resulting product because that the bigger apatite particle of particle diameter and high polymer are difficult to realization is evenly compound preferably.
For improving the dispersibility of apatite, " Biomaterials " 23 (2002): 3919-3926) reported the original position method of formation research that Soichiro Itohet al. carries out, can improve the performance of material to a certain extent.But because its complex technical process, the difficulty of industry amplificationization and realization large-scale production is bigger.
ZL 98111975.1 has reported a kind of direct use nano-grade hydroxy apatite (Ca
10(PO
4)
6(OH)
2, HA) slurry is in (1.5～2.5MPa) carry out compound mode in solution, successfully prepared nano-apatite content at 10～60% polyamide compoiste material under the pressurized conditions.Because this patent system Preparation Method is to carry out compoundly under High Temperature High Pressure, to the requirement height of appointed condition, high temperature also easily causes the oxidation of thermo-sensitive materials such as polyamide, so operating condition is strict.
ZL 200310111033.5 reported and a kind ofly carried out polyamide and nanometer hydroxyapatite composite methods under normal pressure and lower temperature conditions, employing be under the solution system of methanol-water and 30 ℃～65 ℃ conditions, to carry out part polyamide composition and nanometer hydroxyapatite compound.This method can not be used to prepare the composite that comprises as polyamide 1212 polyamide compositions such as grade and nano-apatite, and when used polyamide composition adopts other good solvent such as when glycerol, diethylene glycol equal solvent system, also will prolong at double its recombination time, and in the material between each composition the overall performance of the degree of chemical bonding and composite also remain further to be improved.
ZL200410021985.2 had once reported a kind of multi-element biologic medical composite material and method of containing apatite for preparing through the melt blending mode.Because the time of melt blending preparation process is shorter, reaction in the composite between each composition is insufficient, the microstructure of gained composite is based on the physical property entanglement, and the charging quantity of apatite is limited, when charging quantity is higher than 60%, be difficult to make the apatite composition to be well dispersed in the complex base.
Because clinical demand is extensive and concrete, need make up material according to different conditions of demand, to be suitable for the application at different tissues position with different performance.Although above-mentioned bibliographical information multiple hydroxyapatite/high polymer composite material and preparation method thereof, all still difficultly satisfy the requirement that clinical practice is used satisfactorily.
Summary of the invention
At above-mentioned situation, the present invention at first will provide a kind of reinforced compound nanometer apatite material that can have ideal effect, and further the present invention also will provide said this preparation methods.
The basic composition of reinforced compound nanometer apatite material of the present invention, the complex that in the azeotropic solution system, forms for nano-apatite constituents and at least a medical macromolecular materials composition of particle diameter (5～95) * (5～95) nm, wherein nano-apatite accounts for 1%～80% of said composite weight, is preferably 20%～65%.
Said nanometer osteoid apatite composition can comprise multiple apatite compositions such as the apatite of existing bibliographical information or hydroxyapatite, wherein is preferably OH-or PO in these apatite composition lattice structures especially
4 3-Be CO
3 2-Replace also and contain, Cl ion etc. and to have general formula be Ca just like divalent ion and K, Na ion and F such as Mg, Sr, Ba, Fe, Zn, Cu
10-x/2-m-nM
m(HN)
n(PO
4)
6-x-y(CO
3)
x(OH)
2-2y-z(CO
3)
y(F, Cl)
zThe nanometer osteoid apatite of A type, Type B or the mixed type of form, the M in the general formula can be Mg
2+, Sr
2+, Ba
2+, Fe
2+, Zn
2+, Cu
2+N can be K
+, Na
+0＜x+y≤1.55,0＜z≤0.05,0≤m≤0.36,0≤n≤0.5.This osteoid apatite that contains the carbonate composition increases day by day its application because of the distinctive biological activity of carbonate composition with the similarity of natural bone inorganic constituents.Existing discovering, carbonate wherein can suppress the apatite grain growth, change crystalline growth inside power and crystalline chemical stability (LeGeros, et al., Phosphate Minerals in Human Tissues, inPhosphate Minerals (Berlin), J.Nriagu (eds): Springer, 1984,351-385), and highly active non-phosphate ion such as Na are very easily adsorbed in the lattice surface room of the unsaturated hydroxyapatite of calcium
+, F
-, Cl
-, CO
3 2-Deng, help organizing the absorption with cell, form the active interface of cell and implant.Can effectively improve the bioactive carbonated hydroxyapatite of material, make the area of new bone crystalline substance directly when plane of crystal deposits, also impel cell differentiation (Hulbert SF.In:CRC Handbook of bioactive ceramics Vol 1.T Yamamuro by discharging crystallite, L L Hench, JWilson, Eds.CRC Press.Boston.1990:3-6; Tracy BM.Doemus RH, J Biomed Mater Res.1984; 18:719-721).And calcium is unsaturated, carbonated hydroxyapatite has better dissolution characteristics than pure ha (HA), also helps the material dissolving in vivo and the carrying out of deposition process again.Simultaneously, carbonate is that osteoblast, osteoclast and other osteocyte permeate between bone necessary, and mineral replace and the skeleton reconstruction all relates to osteoblast, osteoclast etc.In composite, adopt the nanometer class bone hydroxyapatite contain carbonate than the crystal of sintering and general hydroxyapatite with form, help to improve the activity of composite, more help tissue substitute more near the biological phosphorus lime stone.Therefore, the calcium of synthetic is unsaturated, to contain the carbonate hydroxyapatite be that osteoid apatite is the first-selection of hard tissue repair implant inorganic constituents.At Li Yubao et.: " Morphology and Composition ofNanograde Calcium Phosphate Needle-Like Crystals Formed by Simple HydrothermalTreatment " (" J.Mater.Sci:Mater.in Med. " 5 (1994): 326-331), Akemi Yasukawa et. " Preparation and Characterization of Carbonated Barium Hydroxyapatites " (" Journal ofColloid and Interface Science " l999, Vol.212:220-227), Hafed El Feki et.: " Sodium andcarbonate distribution in substituted calcium hydroxyapatite " (" Solid State Sciences " 2000, Vol.2:577-586), Yasushi Suetsugu et.: " Structure Analysis ofA-Type Carbonate Apatite bya Single-Crystal X-Ray Diffraction Method " (" Journal of Solid State Chemistry " (2000, Vol.155:292-297) wait document that its preparation and correlational study are all had report.
Said medical macromolecular materials composition is at least a in medical polyamide-based composition or the medical non-polyamide high polymer material.
Said medical polyamide-based composition can comprise existing report and the various polyamide-based composition that uses, as polyamide 6 commonly used; polyamide 66; polyamide 6 12; polyamide 11; polyamide 12; polyamide 1212; polyamide 46; polyamide 2; polyglutamic acid; polyglutamic acid/polyglutamic acid ethyl ester copolymer; polyglutamic acid/poly-leucine copolymer; poly--the methyl glutamate/poly-β-benzyl-L-aspartic acid ester copolymer; poly-hydroxyalkyl-L-glutaminate; poly-N-acyl group-4-hydroxyproline ester; poly-N-acyl group-L-tryptophan ester; collagen; at least a in the medium multiple composition of gelatin.
Said medical non-polyamide high polymer material can extensively be selected in existing report and/or the various high molecular polymers that use equally, for example, can comprise as TPO compositions commonly used such as polyethylene kinds such as hp-ldpe, linear low density polyethylene, high density polyethylene (HDPE), ethylene/vinyl acetate or ethylene/vinyl acetate copolymer; As aromatic polyester constituents commonly used such as polyethylene terephthalate, copolymer of methyl methacrylatestyrene; As polyoxyethylene constituents commonly used such as polyethylene glycol oxide ether acrylate, polyoxyethylene groups styrene; As Merlon constituents commonly used such as poly-propylhomoserin-imido-carbonic ester, poly-propylhomoserin-carbonic esters; As aliphatic polyester constituents commonly used such as polyglycolic acid, polylactic acid, poly-epsilon-caprolactone, poly-(ρ-two mouthful oxane), poly-Alpha-hydroxy two acid esters, glycolic-epsilon-caprolactone copolymer, glycolic-trimethylene carbonate copolymer, glycolic-ρ-two mouthful oxane ketone-trimethylene carbonate copolymer, methylene malonate classes; As cellulose family commonly used such as cellulose acetate, polyvinyl alcohol, polyvinylidene alcohol become to grade at least a in the multiple medical high polymer component of polymer.
Selection to above-mentioned reinforced compound nanometer apatite material constituent of the present invention and/or content ratio, can be according to needs such as the performance requirement of prepared product material and purposes, factor such as the water absorption rate that need realize as product material, desirable biological activity, expection intensity and deciding.For example, the bone conduction, the inductivity that need are good more, and biological activity is high more, and the content of the nano-apatite constituents in the composite is corresponding also just to be required highly more, makes the springform of composite big more; And the content of few nano-apatite constituents, then the bending strength of resulting composite also will be big more.The content of nano-apatite constituents and polar polymer is many more, and the composite water absorption rate of gained is big more; Reduce the content of non-polar polymeric material composition, the water absorption rate of gained composite will be more little.
By evidence, influencing the most important factor of blended compound material mechanical property is size and the shape of a kind of polymer phase in another phase (as decentralized photo) in the dispersion.The compatibility between polymer determines the morphosis of its blend, and and then has determined the performance of blend.Therefore the performance difference of blend has in fact also reflected the difference on its morphosis.
Since the medical macromolecular materials composition in the composition of above-mentioned reinforced compound nanometer apatite material available and use in extensive range, the performance that each composition is seen can there were significant differences, particularly between the bigger composition of polyamide-based composition and non-polyamide high polymer material two class difference.Result of the test shows, when the solubility parameter of non-polyamide high polymer material composition and polyamide-based composition is close when being Δ δ＜0.5, the interphase interface polarity of non-polyamide high polymer material composition and polyamide-based composition is close, and chemistry or physical crosslinking effect can easily directly take place storeroom; But the solubility parameter when therebetween differs when being more greatly Δ δ 〉=0.5, the interphase interface polarity of non-polyamide high polymer material composition and polyamide-based composition differs greatly, alternately be difficult for or can not effectively form chemistry or physical connection, carry out increase-volume by the bulking agent that adds appropriate format and/or proportional quantities, by its polar group that contains and non-polar group, can with the high polymer composition generation chemical reaction or the physical action of opposed polarity, improve the compatibility between the different performance polymer, realize making multiple inhomogeneous high polymer composition, evenly compound in solution system particularly.Owing to provide interaction a large amount of chemistry or physics between bulking agent each component in blend efficiently, making originally, inconsistent two materials have had certain compatibility, thereby the formation between the interface excellent bonds, guaranteed the mechanical property of composite.For example in containing the co-mixing system of polyamide-based composition, these special interactions such as ion-dipole effect in reaction, carboxylate groups and the polyamide-based composition of and carboxyl amino or ligand complex effect, multiple ion by molecular end to or the physical crosslinking that between polymer chain, forms of ion cluster, the compatibility raising that chemical reaction makes blend, thereby can obtain the composite that the compatibility improves, improve the mechanical property of material.
The increase-volume composition select for use should be in its structure, can have with by group or segment identical, similar in the increase-volume high polymer composition, make therebetween polar group that the bonding of chemical can take place, the intersegmental mutual entanglement that physical property then can take place of apolar chain, reduce by two incompatible alternate interface energies thereby reach, realize preferable compatibilization effect.Test shows, in the composite of the above-mentioned form of the present invention, said increase-volume composition generally can be selected wherein any in as compositions such as maleic anhydride grafted polyethylene, (styrene/ethylene/butadiene) block copolymer, polystyrene/glycidyl methacrylate copolymer, (ethylene/methacrylic acid/Sodium methacrylate .) copolymer, (ethylene/methacrylic acid-zinc methacrylate) copolymers, be that ionomer is excellent to select (ethylene/methacrylic acid/Sodium methacrylate .) ionic copolymer wherein.The content of increase-volume composition can be employed non-polyamide high polymer material quality 1%～50%.Use appropriate increase-volume composition and/or consumption, the boundary that can make the heterogeneity composition is in conjunction with good more, and the mechanical property of gained composite is unreasonable to be thought.
The reinforced compound nanometer apatite material of the above-mentioned composition form of the present invention, can be made as can be for continuing any in processing or the convenient various ways of using as powder, granule, fiber, film or bulk etc.
Deep discovers, can have the nano-apatite constituents that can realize comprising the nanometer osteoid apatite in the solution system of azeotropic point and one or more and have desirable compound between identical or different polar polymer under normal pressure.These solution systems can have various ways such as binary, ternary, as water-pure systems such as the water-methanol in the solvent commonly used, water-ethanols; As alcohol-pure systems such as ethanol-glycerol; As alcohol-ester systems such as methanol-ethyl pelargonate, ethanol-ethyl hexanoate, glycerol-ethyl hexanoate, ethanol-cognac oil; Water-alcohol-ester system as water-ethanol-ethyl hexanoate, water-ethanol-cognac oil etc.; Alcohol-benzene system; Water-alcohol-benzene system; Water-dimethyl formamide-ester system; Ethanol-dimethyl sulfoxine-alcohol-dimethyl sulfoxines such as ethyl acetate-ester system; Alcohol-dimethyl sulfoxine-benzene system; And the azeotropic solution system that has azeotropic point as water-dimethyl formamide-toluene, ethanol-glycerol-various ways such as Ketohexamethylene.These solution systems both can be used to prepare the medium system of highly active said nano-apatite constituents, can be used for realizing said nano-apatite crystals and the even compound solution system of said medical macromolecular materials composition again, prepare corresponding nano-apatite or osteoid apatite reinforced composite.Even relate to for example high polymer of polyamide and these two kinds of complete incompatible systems of polyethylene, can realize also that by the solution system that can form azeotropic point satisfied homodisperse is compound, thereby can obtain than the better composite effect of methods such as mechanical blending and have a more composite of satisfactory performance, and help guaranteeing biology (cell) affinity and the mechanical strength of formed composite, by selecting the usage ratio of different polymer and/or change polymer, can also realize the parent/hydrophobicity of gained composite is regulated, obtain to satisfy and to adapt to dissimilar tissues better, the biological product of cell attachment growth needs.
In view of the above, the preparation method of the above-mentioned reinforced compound nanometer apatite material of the present invention can be undertaken by following step:
1 ': obtain the mixed slurry that mass/volume content is 1%～80% nano-apatite constituents by said nano-apatite constituents and dispersant, said dispersant can be selected as deionized water, methanol, ethanol, propanol, ethylene glycol, propylene glycol, glycerol, diethylene glycol, butyldiglycol, phenol, dimethyl sulfoxine, Carbon bisulfide, Ketohexamethylene, chloromethanes, ethyl acetate, toluene, dimethyl ether, cinene, cyclohexane extraction, isobutene., neopentane, ethyl hexanoate, cognac oil, arbitrary single solvent in the multiple solvent such as ethyl caprilate and ethyl pelargonate or by the solvent of at least two kinds of mixed forms.The mixed slurry of said nano-apatite constituents, except that adopting by the formulated mixed slurry of said nano-apatite constituents and said dispersant, can also directly use currently reported or use prepare the slurry of this nano-apatite constituents as medium through wet method with above-mentioned solvent or solution, more easy.
2 ': by said medical macromolecular materials and can form azeotropic system with above-mentioned dispersant---for example above-mentioned variously have the solution system of azeotropic point and be that to dissolve the mass/volume percentage ratio that obtains be 5～50% macromolecule material solution to used macromolecular material good solvent.
3 ': adopting effectively stirring or under the well-beaten condition above-mentioned nano-apatite constituents mixed slurry is being mixed with macromolecule material solution as various can realizations such as sonic oscillations.
4 ': with 3 ' mixed material fully stir to the temperature range that is lower than 80 ℃ of its azeotropic points and carry out compound reaction being higher than 5 ℃ of this mixed material system azeotropic points, obtain said composite.Compound reaction generally can be finished in 1～8 hour.The process of compound reaction can be judged by the state of product in corresponding precipitant: product place precipitant have noted phase separation phenomena then compound reaction do not finish as yet, not phase-splitting then compound reaction is finished.The polarity of using by composite system of selecting for use of precipitant is decided, and the precipitant of composite system deflection polarity (solubility parameter δ 〉=10) can select for use acetone etc. to have organic solvents such as dosage form; The optional deionized water of using of composite system nonpolar partially (δ＜10).
Because the nanometer osteoid apatite is the crystal of high polar surfaces, result of the test shows, when the solvent that dissolves medical macromolecular materials when the dispersant in the nanometer osteoid apatite constituents mixed slurry and being used to all is polar solvent, can obtain said composite after compound in a manner described.But if the dispersant and being used in the nanometer osteoid apatite constituents mixed slurry dissolves one of solvent of medical macromolecular materials for the low pole of solubility parameter value δ＜10 or when nonpolar, need use surfactant, be preferably nonionic surfactant as nanometer osteoid apatite constituents quality 1%～30%.For example, generally can be when the 1st ' step preparation nano-apatite constituents mixed slurry, fully under the mixing condition said mass fraction is 1%～30%, is more preferably 1%～15% at above-mentioned effective stirring or sonic oscillation etc., be preferably 1%～5% surfactant adding nano-apatite constituents slurry, make nano-apatite constituents surface modification, even more ideal dispersion effect is arranged to reach.Surfactant can be selected according to the solvent of dissolving macromolecular material composition, and with good with the compatibility of solvent for use, promptly its solubility parameter value is close to, and can select the surfactant component of ion-type or nonionic.Because non-ionic surface active agent is unionization in aqueous solution, not ionic condition in solution, its hydrophilic group is by oxy radicals such as ether with some and hydroxyls, stability is high, be not subject to the influence of strong electrolytes such as inorganic salts or pH value, therefore and with the other types surfactant compatibility is preferably arranged, preferred nonionic surfactant.For example, alternative surfactant comprises sodium stearate, calcium stearate, sodium alginate, Polyethylene Glycol sodium, dodecylbenzene sodium sulfonate, acrylate copolymer, polyacrylic acid, polybutene acid, acrylic acid copolymer-maleic anhydride and their partly-hydrolysed thing, lignosulphonates, polymine, polyvinyl pyrrolidone, poly maleimide and derivant thereof, polyvinyl pyridine salt, acrylic acid vinylpyridine copolymer, acrylic acid-cationic acrylate copolymer, amphiprotic polyacrylamide, cationic starch plasma type surfactant.Nonionic surfactant can be the nonionic surfactant of semisolid or liquid, for example polystyrene-embedding-polyoxyethylene, stearic acid sorbitan ester, anhydrous sorbitol Triolein, polyoxyethylene sorbitan ester, be selected from the ethylating fatty acid of polyoxy, hydroxylated fatty acid and aliphatic alcohol and particularly be selected from the ethylating Oleum Ricini of polyoxy, the ethylating castor oil hydrogenated of polyoxy, from the ethylating fatty acid of the polyoxy of Oleum Ricini or from the ethylating fatty acid of the polyoxy of castor oil hydrogenated, the methylcellulose any.
Further result of the test also shows, because the dispersant of nano-apatite constituents mixed slurry and being used to dissolves the solvent of macromolecular material the bigger range of choice is arranged all separately, particularly owing to alternatively comprise the in extensive range of polyamide-based and non-polyamide-based medical macromolecular materials composition, corresponding solvent character must have than big-difference, therefore when the dispersant of used nano-apatite constituents mixed slurry with to be used to dissolve the boiling point difference of solvent of macromolecular material not greatly different, for example during boiling point difference＜40 ℃, can prepare said composite in a manner described.During as difference 〉=40 between the solvent boiling point of the boiling point of dispersant in the nano-apatite constituents mixed slurry and dissolving macromolecular material ℃, can be on the basis of aforesaid operations mode, to after mixing dicyandiamide solution in the material and suitably adjusting operation, carry out compound again.Concrete grammar is: after finishing above-mentioned the 1st '～3 ' step, before carrying out the operation of the 4th ' step, earlier mixed material is carried out azeotropic distillation, and simultaneously and in the mixed material system, replenish interpolation can participate in azeotropic and with the organic solvent of solubility parameter difference Δ δ＜0.5 of dissolving macromolecular material solvent for use, to the temperature of material system adjust to boiling temperature difference＜40 ℃ of dissolving the macromolecular material solvent for use after, replenish with the amount that equals the dispersant in the nano-apatite constituents mixed slurry at least and add the used homogeneous solvent of dissolving macromolecular material, the mode by 4 ' step continues compound then.
Further, when the dispersant of used nano-apatite constituents mixed slurry be used to dissolve boiling point difference 〉=40 ℃ of the solvent of macromolecular material, even when great disparity too, by above-mentioned mixed material is being carried out azeotropic distillation and when constantly the mode of supplementing solvent is adjusted the operation of mixed material dicyandiamide solution, the preferred addition manner that replenishes is the solvent that approaches this azeotropic point earlier from boiling point, rising or decline situation according to the material system temperature replace with the solvent approaching with the boiling point of actual change more gradually, with the temperature of progressively adjusting the material system to boiling temperature difference＜40 of dissolving macromolecular material solvent for use ℃.
According to result of the test, when employed medical macromolecular materials in the material contain polyamide-based composition and non-polyamide high polymer material simultaneously, except that can carrying out compound in a manner described and obtain the corresponding composite, following further improved complex method will help to obtain even more ideal effect:
Mode one: will each medical macromolecular materials and selected in case of necessity increase-volume composition be dissolved in the solution mixing of said its good solvent respectively by above-mentioned the 2nd ' step mode, said composition operation temperature and fully under the stirring condition in advance blend compound after, mix with nano-apatite constituents mixed slurry by the 3rd ' step mode again and continue compound; Or
Mode two: by above-mentioned the 3rd ' solution that non-polyamide high polymer material and selected in case of necessity increase-volume composition become with its good solvent with the mode in the 4th ' step and nano-apatite constituents mixed slurry go ahead of the rest compound after, add the solution that become with its good solvent by the polyamide composition again and mix, and by 4 ' and aforesaid mode continue compound.
As above-mentioned, the inventive method can be according to the difference of aspects such as the intensity of clinical required composite, hydrophilic and hydrophobic, degradation rate, select the nano-apatite constituents of corresponding macromolecular material raw material and different content for use, under corresponding suitable azeotropic conditions, carry out compound in the solution system, more meet clinical needs medical composite material thereby prepare.For example, in the reinforced compound nanometer apatite material of the present invention, the content of phosphorus ash stone composition can be regulated and control in 1%～80% scope as required; By many-sides such as the raw material type of polyamide-based composition and/or non-polyamide-based composition, usage ratio being selected and being changed, then can change and adjust the parent/hydrophobic balance of composite, as, the composite that hydrophobicity is strong can be used for the bone reparation of bearing position, the composite that hydrophilic is strong can be used for the not bone reparation of bearing position, then can control the hydrophobic performance and the mechanical property of composite by changing polyamide and poly different proportion; And for example, be used for damaged alternate nano-apatite reinforced polyamide of bone and cellulose acetate composite, or the nano-apatite that is used for repair of cartilage strengthens polyglutamic acid/poly-leucine copolymer and polyvinyl alcohol composite material, the degradation property of its composite also can be by to the change of different degradation rate macromolecule raw material components selection etc., thereby can satisfy the needs of dissimilar tissues, cell attachment growth.With regard to composite itself, the chemical bond key between its each composition is more, and the globality of composite is also even more ideal.Preparation method of the present invention then can not only realize the nano-apatite filling ratio higher than melt-blending process, can also realize the compound of multiple macromolecular material and nano-apatite under more suitable working condition.Especially according to the selection of the characteristic of different azeotropic points, make that the preparation of reinforced compound nanometer apatite material is more simple and practical to solution system.
Below in conjunction with the specific embodiment, foregoing of the present invention is described in further detail again by the accompanying drawing illustrated embodiment.But this should be interpreted as that the scope of the above-mentioned theme of the present invention only limits to following example.Do not breaking away under the above-mentioned technological thought situation of the present invention, various replacements or change according to ordinary skill knowledge and customary means are made all should comprise within the scope of the invention.
Description of drawings
Fig. 1 is the stereoscan photograph with nano-apatite of the present invention/polyamide/polyethylene composite biological material.
Fig. 2 is the cell culture growth conditions (1 day) of material shown in Figure 1, shows that osteoblast can attach on this biomaterial well.
Fig. 3 is the cell culture growth conditions (4 days) of material shown in Figure 1, shows that can be on this biomaterial fine subsides of osteoblast ground is attached, growth, breeding, the material good biocompatibility.
The specific embodiment
Embodiment 1
The nano-apatite slurry adopts document Yi ZUO, Yubao LI, and et al., Journal of Materials Science andTechnology, Vol.19, No.6,2003,628-630 prepares at water-ethylene glycol medium system being attacked by dampness method synthesis mode.Take by weighing the nano-apatite slurry of dry weight 80g, add the dispersant ethanol of 200ml, under well-beaten effect, the nano-apatite slurry is fully disperseed.
The 20g polyamide 6 is dissolved in the 500ml alcohol solvent.Adding nano-apatite slurry and polyamide 6 solution blending closed 0.5～2 hour under abundant stirring condition, control temperature below the azeotropic point temperature of ethylene glycol-alcoholic solution system 5 ℃～10 ℃, realize the evenly compound of nano-apatite and polyamide 6 component, obtain composite.
Embodiment 2
Nano-apatite pulp preparation method is with embodiment 1.Take by weighing the nano-apatite slurry of dry weight 60g, dispersant is a 300ml ethylene glycol, under ultrasonication nano pulp is fully disperseed.
The 20g bovine collagen is dissolved in the 300ml isopropanol solvent, under ultrasonication, nano-apatite slurry and bovine collagen solution blending were closed 0.5～2 hour, control temperature below the azeotropic point temperature of ethylene glycol-aqueous isopropanol system 5 ℃～10 ℃ realizes the evenly compound of nano-apatite and bovine collagen component.
Embodiment 3
Nano-apatite pulp preparation method is with embodiment 1.Take by weighing the nano-apatite slurry of dry weight 40g, dispersant: 50ml water+50ml ethanol+50ml ethyl hexanoate, add 0.6g surface modifier stearic acid sorbitan ester again, under the effect of sonic oscillation, the nano-apatite slurry is fully disperseed and modification.
The 30g high density polyethylene (HDPE) is dissolved in the 500ml ethyl hexanoate solvent.Under the sonic oscillation condition, compound 3～6 hours of nano-apatite slurry and the blend of polyamide 6 solution mixture material, control temperature below the azeotropic point temperature of water-ethanol-ethyl hexanoate solution system 5 ℃～10 ℃ realizes the evenly compound of nano-apatite and high-density polyethylene olefinic constituent.
Embodiment 4
Nano-apatite pulp preparation method is with embodiment 1.Take by weighing the nano-apatite slurry of dry weight 30g, dispersant: 100ml water+40ml ethanol+60ml cognac oil, add 0.6g surface modifier anhydrous sorbitol Triolein again, under the effect of stirring, the nano-apatite slurry is fully disperseed and modification.
The 20g polyamide 66 is dissolved in the 300ml alcohol solvent, 20g ultra-high molecular weight polyethylene and bulking agent 3g (ethylene/methacrylic acid/Sodium methacrylate .) copolymer are dissolved in the 300ml cognac oil solvent.Under stirring condition, compound 3～8 hours of nano-apatite slurry and polyamide 66 solution, the blend of super high molecular polyethylene solution mixed material, control temperature below the azeotropic point temperature of water-ethanol-cognac oil solution system 5 ℃～20 ℃ realizes the evenly compound of nano-apatite and polyamide 66 and ultra-high molecular weight polyethylene.The stereoscan photograph of combination product micro state and result of use situation are respectively as Fig. 1～shown in Figure 3.
Embodiment 5
20g polyglutamic acid/poly-leucine copolymer is dissolved in the 300ml alcohol solvent, 20g low density polyethylene (LDPE) and bulking agent 2g polystyrene/glycidyl methacrylate copolymer are dissolved in the 500ml ethyl hexanoate solvent.Under stirring condition, polyglutamic acid/poly-leucine copolymer solution and low density polyethylene (LDPE) solution blending closed 4～6 hours, control temperature below the azeotropic point temperature of ethanol-ethyl caprilate solution system 5 ℃～20 ℃ makes polyglutamic acid/poly-leucine copolymer and low density polyethylene (LDPE) composite solution.
Nano-apatite pulp preparation method is with embodiment 1.Take by weighing the nano-apatite slurry of dry weight 80g, dispersant: 40ml water+50ml ethanol+80ml ethyl hexanoate, add 0.5g surface modifier anhydrous sorbitol Triolein again, under the effect of stirring, the nano-apatite slurry is fully disperseed and modification.Nano-apatite slurry adding polyglutamic acid/poly-leucine copolymer and low density polyethylene (LDPE) composite solution with modification and after disperseing, control temperature below the azeotropic point temperature of water-ethanol-ethyl hexanoate solution system 5 ℃～15 ℃, stirred 2～3 hours, and realized the evenly compound of nano-apatite and polyglutamic acid/poly-leucine copolymer and low density polyethylene (LDPE).
Embodiment 6
Nano-apatite pulp preparation method is with embodiment 1.Take by weighing the nano-apatite slurry of dry weight 60g, dispersant: 200ml methanol, add 0.6g surface modifier anhydrous sorbitol Triolein again, under ultrasonication, the nano-apatite slurry is fully disperseed and modification.
20g polyamide 1212 is dissolved in the 300ml methanol solvate nano-apatite slurry after adding modification and disperseing.Under agitation, the control temperature is higher than the azeotropic point of water-methanol, constantly adds methanol, discharges the water-methanol blended liquid.When the output of blended liquid during more than 216ml, add polyoxyethylene (30g) solution that is dissolved in the 300ml dimethyl formamide, keep and stirred 4～6 hours, the control temperature near the azeotropic point temperature of methanol-dimethyl formamide solution system ± 5 ℃ the time, realize the evenly compound of nano-apatite and polyamide 1212 and polyoxyethylene component.
Embodiment 7
Nano-apatite pulp preparation method is with embodiment 1.Take by weighing the nano-apatite slurry of dry weight 50g, dispersant: 100ml water+100ml methanol, add the 1g surface modifier again by the polyoxy ethylization fatty acid that castor oil hydrogenated extracts, under ultrasonication, the nano-apatite slurry is fully disperseed and modification.
The 20g polyamide 66 is dissolved in the 300ml glycerol solvent nano-apatite slurry after adding modification and disperseing.Under agitation, the control temperature is higher than the azeotropic point of water-methanol, constantly adds glycerol, discharges the water-methanol blended liquid.When the output of blended liquid during more than 200ml, add poly (l-lactic acid) (30g) solution that is dissolved in 300ml acetone, keep and stirred 3～5 hours, the control temperature 5 ℃～10 ℃ the time, realizes the evenly compound of nano-apatite and polyamide 66 and polylactic acid component below the azeotropic point temperature of glycerol-acetone soln system.
Embodiment 8
Nano-apatite pulp preparation method is with embodiment 1.Take by weighing the nano-apatite slurry of dry weight 70g, dispersant: 150ml ethanol+50ml glycerol, add the 0.6g surface modifier again by the hydrogenation polyoxy ethylization fatty acid that Oleum Ricini extracts, under stirring action, the nano-apatite slurry is fully disperseed and modification.
The 20g polyamide 6 is dissolved in the 300ml glycerol solvent nano-apatite slurry after adding modification and disperseing.Under agitation, the control temperature is higher than the azeotropic point of water-ethanol, constantly adds ethanol, discharges the water-ethanol blended liquid.When the output of blended liquid during more than 330ml, add the polypropylene and (ethylene/methacrylic acid/Sodium methacrylate .) copolymer (6g) solution that are dissolved in the 300ml ethyl pelargonate, keep and stirred 3～6 hours, the control temperature 5 ℃～10 ℃ the time, realizes the evenly compound of nano-apatite and polyamide 6 and polypropylene component below the azeotropic point temperature of ethanol-glycerol-ethyl pelargonate solution system.
Embodiment 9
Nano-apatite pulp preparation method is with embodiment 1.Take by weighing the nano-apatite slurry of dry weight 80g, dispersant: 100ml water+200ml ethanol, fully disperse and modification the nano-apatite slurry under stirring action.
The 10g gelatin is dissolved in the 100ml aqueous solvent, the 10g polyvinyl alcohol is dissolved in 100ml water+100ml alcohol solvent, the nano-apatite slurry after adding modification and disperseing.Under agitation, keep and stirred 3～6 hours, the control temperature 5 ℃～10 ℃ the time, realizes the evenly compound of nano-apatite and gelatin and polyvinyl alcohol component below the azeotropic point temperature of water-ethanol solution system.
Embodiment 10
Nano-apatite pulp preparation method is with embodiment 1.Take by weighing the nano-apatite slurry of dry weight 70g, dispersant: 100ml water+200ml dimethyl sulfoxine, add 3g surface modifier anhydrous sorbitol Triolein again, under stirring action, the nano-apatite slurry is fully disperseed and modification.
15g ultra-high molecular weight polyethylene and 3g (ethylene/methacrylic acid/Sodium methacrylate .) copolymer are dissolved in the ethyl caprilate solvent nano-apatite slurry after adding modification and disperseing.Under agitation, the control temperature is higher than the azeotropic point of water-dimethyl sulfoxine, constantly adds ethyl caprilate, discharge water-dimethyl sulfoxine blended liquid.When the output of blended liquid during more than 380ml, add polyamide 6 12 solution that are dissolved in the 300ml dimethyl sulfoxine, kept stirring or sonic oscillation 6～8 hours, control temperature below the azeotropic point temperature of solution system 5 ℃～10 ℃ realizes the evenly compound of nano-apatite and high amide 612 and ultra-high molecular weight polyethylene component.
Embodiment 11
Nano-apatite pulp preparation method is with embodiment 1.Take by weighing the nano-apatite slurry of dry weight 60g, dispersant: 50ml water+200ml ethanol, add 4g surface modifier anhydrous sorbitol Triolein again, under stirring action, the nano-apatite slurry is fully disperseed and modification.
The 20g cellulose diacetate is dissolved in the 200ml cyclohexanone solvent nano-apatite slurry after adding modification and disperseing.Under agitation, the control temperature is higher than the azeotropic point of water-ethanol, constantly adds Ketohexamethylene, discharges the water-ethanol blended liquid.When the output of blended liquid during more than 355ml, add collagen (20g) solution that is dissolved in 200ml glycerol solution, keep and stirred 4～6 hours, the control temperature 5 ℃～20 ℃ the time, realizes the evenly compound of nano-apatite and gelatin and cellulose diacetate component below the azeotropic point temperature of Ketohexamethylene-glycerol solution system.
Embodiment 12～22
Nano-apatite composition in raw materials used in the foregoing description 1～11 preparation process is used general molecular formula Ca respectively
10-x/2-m-nM
m(HN)
n(PO
4)
6-x-y(CO
3)
x(OH)
2-2y-z(CO
3)
y(F, Cl)
z(M in the formula can be respectively Mg
++, Sr
++, Ba
++, Fe
++, Zn
++, Cu
++N can be respectively K
+, Na
+0＜x+y≤1.55,0＜z≤0.05,0≤m≤0.36,0≤n≤0.5) the nanometer osteoid apatite of range of structures is replaced, and all the other raw materials and operating condition and mode of operation all do not change.The source of nanometer osteoid apatite or preparation method can be carried out with reference to the mode of above-mentioned existing bibliographical information.The gained performance of composites product with corresponding embodiment respectively is suitable.
Claims (10)
1. the preparation method of reinforced compound nanometer apatite material is characterized in that being undertaken by following mode:
1 ': by particle diameter is that the nano-apatite constituents of (5～95) * (5～95) nm and dispersant obtain the mixed slurry that mass/volume content is 1%～70% nano-apatite constituents, and said dispersant is a deionized water, methanol, ethanol, propanol, ethylene glycol, propylene glycol, glycerol, diethylene glycol, butyldiglycol, phenol, dimethyl sulfoxine, Carbon bisulfide, Ketohexamethylene, chloromethanes, ethyl acetate, toluene, dimethyl ether, cinene, cyclohexane extraction, isobutene., neopentane, ethyl hexanoate, cognac oil, at least a in ethyl caprilate and the ethyl pelargonate;
2 ': by medical macromolecular materials with can form azeotropic system with above-mentioned dispersant and be that to dissolve the mass/volume percentage ratio that obtains be 5～50% macromolecule material solution for used macromolecular material good solvent, said medical macromolecular materials composition is at least a in polyamide-based composition or the non-polyamide high polymer material, and wherein said polyamide-based composition comprises polyamide 6, polyamide 66, polyamide 6 12, polyamide 11, polyamide 12, polyamide 1212, polyamide 46, polyamide 2, polyglutamic acid, polyglutamic acid/polyglutamic acid ethyl ester copolymer, polyglutamic acid/poly-leucine copolymer, poly--the methyl glutamate/poly-β-benzyl-L-aspartic acid ester copolymer, poly-hydroxyalkyl-L-glutaminate, poly-N-acyl group-4-hydroxyproline ester, poly-N-acyl group-L-tryptophan ester, collagen, at least a in the gelatin; Said non-polyamide high polymer material comprises at least a in TPO, aromatic polyester class, polyoxyethylene, polylactic acid, Merlon, aliphatic polyester, cellulose, the polyvinyl alcohol;
3 ': fully under the stirring condition above-mentioned nano-apatite constituents mixed slurry is mixed with macromolecule material solution;
4 ': with 3 ' mixed material that obtains fully stirs to the temperature range that is lower than 80 ℃ of its azeotropic points and carries out compound reaction being higher than 5 ℃ of mixed material system azeotropic points, obtains said composite.
2. preparation method as claimed in claim 1, it is characterized in that one of dispersant used in said 1 ' step or 2 ' step or solvent for the low pole of solubility parameter value δ＜10 or when nonpolar, need use the surfactant as nano-apatite constituents quality 1%～30%.
3. preparation method as claimed in claim 2 is characterized in that said surfactant is a nonionic surfactant.
4. preparation method as claimed in claim 1, during difference 〉=40 of the dispersant boiling point that it is characterized in that said nano-apatite constituents mixed slurry and the solvent boiling point of dissolving macromolecular material ℃, before carrying out the operation of the 4th ' step, earlier mixed material is carried out azeotropic distillation, and in the mixed material system, replenish simultaneously interpolation can participate in azeotropic and with the organic solvent of solubility parameter difference A δ＜0.5 of dissolving macromolecular material solvent for use, to the temperature of material system adjust to boiling temperature difference＜40 ℃ of dissolving the macromolecular material solvent for use after, replenish with the amount that equals the dispersant in the nano-apatite constituents mixed slurry at least and add the used homogeneous solvent of dissolving macromolecular material, the mode by 4 ' step continues compound then.
5. preparation method as claimed in claim 4, it is characterized in that saidly carrying out 4 ' azeotropic process that carries out is earlier replenished the organic solvent that adds for being begun by the solvent of boiling point near actual azeotropic point during the step operation, gradually replace with and change the approaching solvent of boiling point, the temperature of adjusting the material system gradually to boiling temperature difference＜40 of dissolving macromolecular material solvent for use ℃.
6. as the described preparation method of one of claim 1 to 5, it is characterized in that said medical macromolecular materials when containing polyamide-based composition and non-polyamide high polymer material simultaneously, it is compound to adopt the mode of one of the following to carry out, and obtains said composite:
Mode one, to each medical macromolecular materials and increase-volume composition be dissolved in the solution mixing of said its good solvent by the 2nd ' step mode respectively, after the blend of going ahead of the rest under said composition operation temperature and the abundant stirring condition is compound, mix with nano-apatite constituents mixed slurry by 3 ' mode again and continue compound, said increase-volume composition is a maleic anhydride grafted polyethylene, or (styrene/ethylene/butadiene) block copolymer, polystyrene/glycidyl methacrylate copolymer, (ethylene/methacrylic acid/Sodium methacrylate .) copolymer, any in (ethylene/methacrylic acid-zinc methacrylate) copolymer; Or
Mode two, by 3 ' with 4 ' mode solution that non-polyamide high polymer material and said increase-volume composition are become with its good solvent and nano-apatite constituents mixed slurry go ahead of the rest compound after, add the solution that become with its good solvent by the polyamide composition again and mix, by 4 ' mode continue compound.
7. reinforced compound nanometer apatite material, it is characterized in that the complex that formed in the azeotropic solution system of claim 1 by nano-apatite constituents that basic composition is particle diameter (5～95) * (5～95) nm and at least a medical macromolecular materials composition, wherein nano-apatite accounts for 1%～80% of said composite weight; Said nano-apatite constituents is for having general structure Ca
10-x/2-m-nM
m(HN)
n(PO
4)
6-x-y(CO
3)
x(OH)
2-2y-z(CO
3)
y(F, Cl)
zOsteoid apatite, apatite or structure in phosphate radical or hydroxyl be the osteoid apatite that carbonate replaced, the M in the general formula is Mg
2+, Sr
2+, Ba
2+, Fe
2+, Zn
2+, Cu
2+N is K
+, Na
+0＜x+y≤1.55,0＜z≤0.05,0≤m≤0.36,0≤n≤0.5; Said medical macromolecular materials composition is at least a in polyamide-based composition or the non-polyamide high polymer material, and wherein said polyamide-based composition is for comprising polyamide 6, polyamide 66, polyamide 6 12, polyamide 11, polyamide 12, polyamide 1212, polyamide 46, polyamide 2, polyglutamic acid, polyglutamic acid/polyglutamic acid ethyl ester copolymer, polyglutamic acid/poly-leucine copolymer, poly--the methyl glutamate/poly-β-benzyl-L-aspartic acid ester copolymer, poly-hydroxyalkyl-L-glutaminate, poly-N-acyl group-4-hydroxyproline ester, poly-N-acyl group-L-tryptophan ester, collagen, at least a in the gelatin; Said non-polyamide high polymer material comprises at least a in TPO, aromatic polyester class, polyoxyethylene, polylactic acid, Merlon, aliphatic polyester, cellulose, the polyvinyl alcohol.
8. reinforced compound nanometer apatite material as claimed in claim 7 is characterized in that it is 20%～65% that said nano-apatite constituents accounts for said composite weight.
9. reinforced compound nanometer apatite material as claimed in claim 7, it is characterized in that containing simultaneously in the said medical macromolecular materials composition polyamide-based composition and non-polyamide high polymer material and its solubility parameter difference Δ δ 〉=at 1 o'clock, account for the increase-volume composition of non-polyamide high polymer material quality 1%～50% in the composition in addition, said increase-volume composition is a maleic anhydride grafted polyethylene, or (styrene/ethylene/butadiene) block copolymer, polystyrene/glycidyl methacrylate copolymer, (ethylene/methacrylic acid/Sodium methacrylate .) copolymer, any in (ethylene/methacrylic acid-zinc methacrylate) copolymer.
10. as the described reinforced compound nanometer apatite material of one of claim 7 to 9, it is characterized in that product is one of powder, granule, fiber, film or blocky form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100223265A CN100348278C (en) | 2005-12-19 | 2005-12-19 | Reinforced compound nanometer apatite material and its prepn process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100223265A CN100348278C (en) | 2005-12-19 | 2005-12-19 | Reinforced compound nanometer apatite material and its prepn process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1810305A CN1810305A (en) | 2006-08-02 |
| CN100348278C true CN100348278C (en) | 2007-11-14 |
Family
ID=36843515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100223265A Expired - Fee Related CN100348278C (en) | 2005-12-19 | 2005-12-19 | Reinforced compound nanometer apatite material and its prepn process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100348278C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104324415B (en) * | 2014-11-04 | 2015-11-18 | 四川国纳科技有限公司 | Polybasic amino acids polymer-hydroxyl apatite bone repairing material, support type implant and preparation method |
| CN107189372A (en) * | 2017-06-26 | 2017-09-22 | 俞惠英 | A kind of antibacterial polyester film and preparation method thereof |
| CN111671981A (en) * | 2020-06-24 | 2020-09-18 | 杭州锐健马斯汀医疗器材有限公司 | Absorbable composite material for interface screw sheath and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002274821A (en) * | 2001-03-23 | 2002-09-25 | Asahi Kasei Corp | Planar apatite and production method thereof |
| CN1559624A (en) * | 2004-03-09 | 2005-01-05 | 四川大学 | Multi-component biomedical composite material containing apatite and preparation method thereof |
-
2005
- 2005-12-19 CN CNB2005100223265A patent/CN100348278C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002274821A (en) * | 2001-03-23 | 2002-09-25 | Asahi Kasei Corp | Planar apatite and production method thereof |
| CN1559624A (en) * | 2004-03-09 | 2005-01-05 | 四川大学 | Multi-component biomedical composite material containing apatite and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1810305A (en) | 2006-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zadegan et al. | Synthesis and biocompatibility evaluation of cellulose/hydroxyapatite nanocomposite scaffold in 1-n-allyl-3-methylimidazolium chloride | |
| Huang et al. | Gold nanoparticles-loaded polyvinylpyrrolidone/ethylcellulose coaxial electrospun nanofibers with enhanced osteogenic capability for bone tissue regeneration | |
| Shuai et al. | Surface modification of nanodiamond: toward the dispersion of reinforced phase in poly-l-lactic acid scaffolds | |
| Duan et al. | Three-dimensional nanocomposite scaffolds fabricated via selective laser sintering for bone tissue engineering | |
| Zhang et al. | The development of collagen based composite scaffolds for bone regeneration | |
| Fabbri et al. | Porous scaffolds of polycaprolactone reinforced with in situ generated hydroxyapatite for bone tissue engineering | |
| Backes et al. | Engineering 3D printed bioactive composite scaffolds based on the combination of aliphatic polyester and calcium phosphates for bone tissue regeneration | |
| Wang et al. | Improved mechanical properties of hydroxyapatite/poly (ɛ-caprolactone) scaffolds by surface modification of hydroxyapatite | |
| Qian et al. | Enhancing bone scaffold interfacial reinforcement through in situ growth of metal–organic frameworks (MOFs) on strontium carbonate: Achieving high strength and osteoimmunomodulation | |
| Van Ho et al. | Novel TOCNF reinforced injectable alginate/β-tricalcium phosphate microspheres for bone regeneration | |
| CN101721740A (en) | Bone tissue engineering bracket material and preparation method and application thereof | |
| CN103342555A (en) | Strontium magnesium-doped nano-hydroxyapatite and preparation method thereof | |
| Prasad et al. | Surfactant-assisted synthesis of hydroxyapatite particles: a comprehensive review | |
| Ding et al. | Developing a biodegradable tricalcium silicate/glucono-delta-lactone/calcium sulfate dihydrate composite cement with high preliminary mechanical property for bone filling | |
| Nicoletti et al. | Effects of different crosslinking conditions on the chemical–physical properties of a novel bio-inspired composite scaffold stabilised with 1, 4-butanediol diglycidyl ether (BDDGE) | |
| CN101235194B (en) | Polylactic acid-modified wollastonite composite material and preparation method thereof | |
| Rashidi et al. | 3D printed hetero-layered composite scaffold with engineered superficial zone promotes osteogenic differentiation of pre-osteoblast MC3T3-E1 cells | |
| CN100348278C (en) | Reinforced compound nanometer apatite material and its prepn process | |
| Shi et al. | Fabrication, properties, and biomedical applications of calcium-containing cellulose-based composites | |
| Cheng et al. | Engineering poly (lactic-co-glycolic acid)/calcium carbonate microspheres with controllable topography and their cell response | |
| US20180015198A1 (en) | Method of making injectable cements | |
| Zhang et al. | An artificial bone filling material of poly L-lactic acid/collagen/nano-hydroxyapatite microspheres: preparation and collagen regulation on the property | |
| US9226993B2 (en) | Biomaterial scaffolds with keratin for tissue engineering | |
| Veiga et al. | Tackling current production of HAp and HAp-driven biomaterials | |
| CN114129771B (en) | Flexible bioceramic scaffold with imitating sponge spicules microstructure and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071114 Termination date: 20131219 |